Protagonist Therapeutics, Inc (PTGX) — Analysis Summary
Protagonist Therapeutics, Inc (PTGX) has a market cap of $8.79B with year-over-year revenue growth of -89.4%. Net margin stands at -282.8%. The stock trades at a P/E ratio of -76.6.
Key Takeaways
- Revenue changed -89.4% year-over-year
- Net margin of -282.8%
- P/E ratio of -76.6
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, PTGX posted revenue growth of -89.4% and trades at a P/E of -76.6.
Protagonist Therapeutics, Inc (PTGX)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -192.4% — severe operating losses
Net margin at -154.9% — losses exceed revenue (possible one-time charges)
Free cash flow turned negative after being positive in the prior period.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
131
Headquarters
NEWARK, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.